14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CSTL vs NDRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Castle Biosciences, Inc. (CSTL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CSTL carries a Unified Composite Score of 49.3/100 (HOLD) at $32.75 (N/M Forward P/E, -7.4% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: CSTL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.9); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CSTL vs NDRA. Trailing 12-month operating profitability (CSTL -7.4% vs NDRA 0.0%) and valuation multiples (CSTL N/M vs NDRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CSTL vs NDRA Key Questions & Quantitative Answers
As of Nov 16, 2026, Castle Biosciences, Inc. (CSTL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CSTL carries a Unified Composite Score of 49.3/100 (HOLD) at $32.75 (N/M Forward P/E, -7.4% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CSTL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.9); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CSTL leads the Growth & Scale pillar: CSTL posts +23.9% YoY revenue growth and -51.6% YoY earnings growth on $377M TTM revenue (77.1% gross margin, -7.4% operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CSTL generates $377M in USD-normalized revenue versus N/A for NDRA. In operating R&D and SG&A reinvestment, CSTL deploys 84.5% of Rev ($319M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.
CSTL screens cheaper on headline valuation multiples. CSTL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.8x EV/Revenue (-3.2% EBITDA margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CSTL (-4.9% ROE) versus NDRA (-152.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CSTL carries 41.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 57% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.